Going International with Gilead Sciences Inc.

Gilead Sciences Inc. (NASDAQ: GILD) is a large US biotech stock specialising in antiviral drugs to treat patients suffering from HIV, hepatitis C, influenza and other medical conditions. As the world’s leading anti-viral company, Gilead holds strong market positions in some very lucrative markets. For investors the attraction of Gilead is its valuation, free cash-flow and potential growth opportunity.

Gilead Sciences Inc. (NASDAQ: GILD) is an international stock currently in the Cadence portfolio and was the first offshore listed position in the fund, initiated in mid-2014.  

In summary, Gilead is a large US biotech stock specialising in antiviral drugs to treat patients suffering from HIV, hepatitis C, influenza and other medical conditions.

In 2014 it generated approximately US$25bn in revenue and currently has a market capitalisation of US$180 billion (this is larger than any company listed on the ASX). As the world’s leading anti-viral company, Gilead holds strong market positions in some very lucrative markets.

Click here to read the full article.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Join the Conversation...

There are comments posted so far.

If you'd like to join this conversation, please login or sign up here

Related Articles